Blood group (ABOi) incompatible kidney transplantation

Delivering the best in care

UHB is a no smoking Trust

To see all of our current patient information leaflets please visit www.uhb.nhs.uk/patient-information-leaflets.htm
Blood group incompatible (ABOi) kidney transplantation

This leaflet gives you information specifically about blood group incompatible (ABOi) kidney transplantation.

It explains the reasons for undertaking this type of transplantation and its risks and benefits.

An information sheet for live kidney transplantation is also available and this leaflet should also be read alongside the live kidney transplantation leaflet.

What is ABO incompatible transplantation

About 30% of potential live donors for kidney transplantation are found to be blood group incompatible. This means that antibodies in the patient with kidney disease will reject the kidney of the donor because of different blood group types. Previously, if this transplant had been performed, the kidney would have immediate rejection. The table below shows blood group incompatibilities.

<table>
<thead>
<tr>
<th>Recipient</th>
<th>O</th>
<th>A</th>
<th>B</th>
<th>AB</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blood Group</strong></td>
<td>O</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>O</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>A</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>B</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>AB</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>
Since the 1980s, techniques have been developed to safely overcome this barrier by reducing antibodies before transplantation. This has enabled many more patients to receive kidney transplants around the world.

The results of blood group incompatible kidney transplants are comparable to those of live donor blood group compatible and at 1 year about 90–95% of transplanted live donor kidney transplants would be expected to be functioning.

These types of transplants have been performed throughout the world.

How is the patient prepared for an ABOi transplant?

Following discussion with your doctor, and assessment of your ABO antibody levels, a plan is drawn up detailing when you will need to come to hospital for appointments and for treatments.

Immunoadsorption is used to remove blood group antibodies from your blood on a machine in a process resembling a haemodialysis session. The session lasts 3–4 hours and the number of sessions is dependent on the amount of antibody present. Most people require 2–4 sessions, but some people require a lot more.

Your blood group antibodies will be monitored during this process and the transplant will only proceed if the antibody levels are sufficiently low. Occasionally (about 1 in 10 cases) it may not be possible to reduce your antibodies.

Sometimes high levels of antibodies come back after transplantation and further sessions of immunoadsorption are required.

You will start your anti-rejection medications 4–6 days before transplantation.
When does this take place?

If you do not have a dialysis line or fistula already, you will need to have a line inserted two weeks before your transplantation date. The dialysis line will be inserted in the renal procedure room, and you will be admitted as a day case to Ambulatory Care. The immunoadsorption sessions are carried out on the third floor in our Dialysis Unit (Ward 301) at specified times depending on the amount of blood group antibody present. These are carried out the week before transplantation and are done as a day attendance. It is necessary to come for repeat ABO antibody levels testing prior to immunoabsorption to monitor the antibody levels. This will take place with the Kidney Assessment Team (KAT) also on the third floor Ward 301.

What are the risks?

As with all kidney transplants, there are risks associated with the operation and the anti-rejection medications. In addition to these, there is a slightly higher risk of rejection which associated with higher levels of blood group antibodies.

Antibody removal
Who is suitable for this type of transplant?
You will need to have been assessed as medically fit to receive a transplant, and the potential donor will need to have been assessed as medically fit to donate a kidney.

Blood samples will be taken to measure the amount of blood group antibody present in the body. The amount of antibody present will guide whether the transplant can take place and how much treatment is necessary before the transplant operation. If your antibodies are too high at this stage, we would ask whether you would consider the paired exchange programme (ask your doctor about this programme).

Frequently asked questions

Do I have to have this type of transplant?
No. You can stay on dialysis or on the National Kidney Transplant Waiting List or participate in the Paired Exchange Programme. It is important to talk with your doctors about the benefits and risks of blood group incompatible transplantation and not having a transplant at present.

Are there any age restrictions on receiving a kidney from an ABOi donor?
There are no strict age restrictions, however, the potential recipient must be in good general health and may require further investigations to assess their overall fitness before the procedure can go ahead. Each donor-recipient pair will be considered on a case by case basis.

How long does the evaluation for ABOi transplantation take?
This is usually determined by the donor assessment. The overall time from entering the live donor transplant programme to receiving a kidney is 6–18 weeks depending on many factors. For the recipient, special blood tests need to be taken and these will tell us the antibody levels within a week. Sometimes the
antibody levels in the recipient are too high to proceed, or other antibodies (non-ABO) are present that may require a different approach to treatment. Occasionally the recipient will require further medical assessment.

**Will the recipient need to be in hospital before the transplant?**
You will require daily reviews and increased treatment in the 10-14 days prior to transplantation. This treatment is performed as an outpatient, but will be discussed on an individual patient basis.

**How long is the hospital stay after the transplant?**
Most people receiving a transplant will be in hospital between 5-10 days. Donors are usually in hospital for between 3-5 days.

**Websites**
British Transplant Society
www.bts.org.uk

NHS Blood and Transplant
www.nhsbt.org.uk

KPA (Kidney patient advisory group)
www.kidney.org.uk

**Contacts**
Dr Simon Ball, Consultant Nephrologist UHB
Mr Andrew Ready, Consultant Transplant Surgeon UHB

Enquire about ABO incompatible transplantation:
Surinder Jandu – Antibody incompatible Transplant Coordinator
Telephone: 0121 371 5834 or 07917 077680

Live Donor Kidney Transplant Co-ordinators
Telephone: 0121 371 5845
The Kidney Disease Research Fund at UHB

The renal unit at UHB is one of the largest in the United Kingdom with more than 1,000 patients on dialysis, 850 patients with functioning transplants and 5,000 patients seen each year in the clinics. The renal transplant programme undertakes more than 150 transplants per year of which around half will be live donor transplants.

University and NHS staff work together to provide excellence in clinical care, research and teaching. The research undertaken by the department ranges from basic laboratory science to the optimisation of established treatments. From ‘high-tech’, modern molecular biology to ‘low-tech’ studies of patient transport and where best to site new dialysis units. In the field of transplantation there is particular interest in the mechanisms by which kidney transplants gradually fail over the long-term (approximately 50% do so by 12 years).

The Kidney Research Fund at UHB provides vital start-up funds for studies that go on to obtain support from national bodies such as KRUK and the Wellcome Trust. The outcomes of our research are regularly presented or published in peer reviewed journals. Most importantly they impact on the every day treatment of our patients who benefit further from care within a ‘research active’ environment. For example charitable funds allow the introduction of new treatments before they become routinely available via the NHS. This was true of the first ABO incompatible transplant to happen at UHB.

If you want to know more about the Kidney Research Fund contact:

Phone: 0121 371 5842
Fax: 0121 371 5858
Email: ruth.darling@uhb.nhs.uk
The Trust provides free monthly health talks on a variety of medical conditions and treatments. For more information visit www.uhb.nhs.uk/health-talks.htm

Renal
Queen Elizabeth Hospital Birmingham
Mindelsohn Way
Edgbaston
Birmingham B15 2WB
Telephone 0121 627 2000